The research looked at patients who qualified for the antiviral through age or health conditions. Those who took it shortly after infection were 26 percent less likely to have symptoms 90 days later.
Paxlovid May Reduce Risk of Long Covid in Eligible Patients, Study Finds
The New York Times – Business:
This post first appeared in The New York Times – Business. Read the original article.
Written by
in